Summer Management Meeting Presentation - Yale University：夏季管理会议演示-耶鲁大学.ppt

Sponsors Medical device simplifies the treatment of venous disease to reach a huge untreated market  Technology from Yale School of Medicine Inexpensive to manufacture Easy to use  No anesthesiaNo capital investment Simple vein accessOffice environment Shortest procedure time Reduced convalescence Reduced complications  Reduced pain Physiological cause of varicose veins Target: Saphenous and Related Veins Target: Saphenous and Related Veins Current Therapeutic Options Surgery Sclerotherapy Interventional Techniques- heat Laser Radiofrequency No Satisfactory Solution  Surgical stripping and ligation Invasive procedure General anesthesia Hospitalization Laser and RF present difficulties Costs Procedure time Difficult to use Success of Vein Stripping Ligation % of patients with no reflux after treatment: 91% at 1 year 87% at 2 years 71% at 5 years Sclerosing Solutions Reticular and small varicose Injection of up to 1cc per site. No more than 10cc per session Sclerosing solutions are surfactants. Safe and in use for decades. Liquid sclerotherapy ineffective in large varicosities and the GSV. Injection Techniques: Varicose Veins Sclerotherapy dilution problem Liquid sclerosant immediately dilutes with blood. Ineffective concentration at the vessel wall. ClariVein? “mechanically enhanced endovenous chemical ablation” Small-caliber infusion catheter used to increase the effectiveness of a sclerosing agent by delivering the agent to the vein wall while simultaneously inducing spasm and irritating and destroying the endothelium to ablate diseased veins in place in a few minutes. Vascular Insights LLC “The best way to predict the future is to invent it.” Alan Kay, Apple/ Xerox Valuable IP Portfolio Yale University has applied for a patent Vascular Insights has exclusive rights to the IP Vascular Insights applied for additional patents One of the Largest Markets for any chronic condition 75 to 150 million people in North America and W